• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home AI Roundup

2MM: AI Roundup – Pancreatic Cancer Prediction Breakthrough, Retinal Stroke Risk Maps, Microsoft’s MAI‑DxO Diagnostic Upset, and Kenya’s AI Consult Real‑World Win [July 28th, 2025]

byDeepti Shroff
July 28, 2025
in AI Roundup
Reading Time: 4 mins read
2 Minute Medicine AI Roundup editorial illustration
Share on FacebookShare on TwitterShare on LinkedIn

 

AI scans detect pancreatic cancer years before symptoms emerge
A new deep learning model may have cracked one of oncology’s toughest challenges: spotting pancreatic cancer early enough to save lives. Researchers showed that the algorithm, trained on standard abdominal CT scans, can detect pancreatic ductal adenocarcinoma up to three years before clinical diagnosis, achieving an AUROC above 0.92 according to a March 2025 preprint. This timeline is remarkable given that most cases are detected far too late for curative surgery. A Harvard Medical School study similarly flagged high‑risk individuals from EHR data, strengthening the case for multi‑modal AI screening. Given that the five‑year survival rate remains under 5 percent, early‑detection tools could be game‑changing. Because the new model works on non‑contrast CTs, it could be integrated into routine hospital workflows without specialized protocols. Trials are expected to begin in the U.S. and Europe before year’s end. Experts caution that clinical validation is still ahead, but optimism is high thanks to robust performance across multiple cohorts. If successful, this could become one of the first AI tools to offer multi‑year lead time on a historically deadly cancer.

Retinal scans powered by AI predict stroke risk with surprising accuracy
Your next eye exam might also assess your stroke risk. A new study in npj Digital Medicine found that deep learning models analyzing retinal images can predict ischemic stroke over a 10‑year horizon with ~70 percent sensitivity. Researchers at University College London trained their system on over 85,000 eye images from the UK Biobank, then combined imaging features with clinical data to improve accuracy. Compared with the Framingham score, this approach saw a 5 percent AUROC boost, revealing the retina’s unique window into cerebrovascular health. Because the tool is non‑invasive and inexpensive, the team plans to integrate it into routine optometry and NHS screenings by early 2026. The authors also highlight its potential in underserved regions where access to CT angiography or carotid ultrasound is limited. This development follows broader momentum in using ocular biomarkers for systemic‑disease detection, from Alzheimer’s to hypertension. Ultimately, it’s a compelling case for expanding preventive screening through retinal scans.

Microsoft’s MAI‑DxO beats doctors at complex diagnoses under pressure
Microsoft’s new medical AI, MAI‑DxO, appears to out‑diagnose physicians on tough clinical cases, at least under test conditions. The system solved 85.5 percent of 304 cases from the New England Journal of Medicine, while human doctors got just 20 percent correct, as reported by the Financial Times. MAI‑DxO uses up to five specialized agents, including OpenAI’s o3 model, that simulate internal debates before reaching a conclusion. In addition to diagnostic accuracy, the model reportedly cut unnecessary tests and reduced decision costs, according to CMSWire. While not yet cleared for clinical use, Microsoft intends to release a research API by fall 2025. The Guardian noted the tool’s performance in high‑pressure scenarios, while a WHO advisor commented on its promise for low‑resource settings. Though still research‑grade, MAI‑DxO offers a glimpse into a future where AI can augment, if not outperform, clinicians when cases get complicated.

Kenya’s AI Consult cuts diagnostic errors by 16 percent in live clinics
In a major real‑world test of AI in medicine, Penda Health and OpenAI piloted a clinical decision‑support system called AI Consult across 16 Nairobi clinics serving over 20,000 patients. The tool reduced diagnostic mistakes by 16 percentand treatment errors by 13 percent, according to TIME. Rather than taking over decisions, the system uses a color‑coded signal (green/yellow/red) to quietly alert providers to possible errors, a design detailed in PSL Hub. It acts as a silent copilot, offering backup without intruding. Providers reported increased confidence, especially junior clinicians, as described in an OpenAI community post. A Stat News feature noted the success of the hybrid model in a resource‑constrained environment. With expansion planned across East Africa, the program is shaping up as a model for ethical, scalable AI in global health.
These stories show AI’s expanding global role across early detection, screening, diagnosis, and decision support.

FDA approvedFor pancreatic cancer: Rasonque (daraxonrasib), Aug 26, 2026→

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

Tags: artificial intelligencecancerCT scanframingham scoreoncologyradiologystroke risk
Previous Post

2 Minute Medicine Rewind July 27, 2025

Next Post

Red cell distribution width to albumin ratio may be a useful prognostic marker in the critical care setting

RelatedReports

A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
An illustration depicting the colon with IV bags on either side, symbolizing sequential therapy paths in colorectal cancer treatment.
Gastroenterology

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

October 29, 2026
A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
An illustration featuring a heart within a house, with a stethoscope, a scale, and medication, symbolizing heart failure home hospital care.
Artificial Intelligence

An artificial intelligence model demonstrates the potential for improving the efficiency of structural heart disease screening using electrocardiograms

October 21, 2026
Next Post

Red cell distribution width to albumin ratio may be a useful prognostic marker in the critical care setting

Medicine safety collage: a brass balance scale with a two-tone capsule on one pan and a blue paper shield on the other

Prophylactic vancomycin may reduce recurrent Clostridioides difficile infection but increases antimicrobial resistance

Stroke recovery collage: a calm man in a sweater beside a brain with teal arteries, an empty speech bubble and a squeeze ball

Early anticoagulation after stroke decreases recurrence without increasing bleeding in patients with atrial fibrillation

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis
  • Intraosseous cefuroxime (Ceftin) may improve tissue delivery compared to intravenous administration during total knee arthroplasty
  • 2 Minute Medicine Rewind November 2, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.